Efficacy of DB289 in Thai Patients withPlasmodium vivaxor Acute, UncomplicatedPlasmodiumfalciparumInfections
The Journal of Infectious Diseases2005Vol. 192(2), pp. 319–322
Citations Over TimeTop 10% of 2005 papers
Patrick Yeramian, Steven R. Meshnick, Srivicha Krudsood, Kobsiri Chalermrut, Udomsak Silachamroon, Noppadon Tangpukdee, James L. Allen, Reto Brun, Jesse J. Kwiek, Richard R. Tidwell, Sornchai Looareesuwan
Abstract
DB289 is a promising new antimalarial compound that could become an important component of new antimalarial combinations.
Related Papers
- → TAFENOQUINE FOR THE TREATMENT OF RECURRENT PLASMODIUM VIVAX MALARIA(2007)40 cited
- → Diagnostic and Therapeutic Pitfalls Associated with Primaquine-Tolerant Plasmodium vivax(2005)37 cited
- → Short Report: Primaquine-Tolerant Plasmodium vivax in an Italian Traveler from Guatemala(1996)16 cited
- → ¿Cuánta primaquina es necesaria para erradicar los hipnozoitos de Plasmodium vivax?(2006)5 cited
- → Therapeutic principles of primaquine against relapse ofPlasmodium vivaxmalaria(2018)2 cited